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Frontotemporal lobar degeneration (FTLD) often overlaps clinically with corticobasal syndrome (CBS) and
progressive supranuclear palsy (PSP), both of which have prominent eye movement abnormalities.To investigate
the ability of oculomotor performance to differentiate between FTLD, Alzheimer’s disease, CBS and PSP,
saccades and smooth pursuit were measured in three FTLD subtypes, including 24 individuals with frontotem-
poral dementia (FTD), 19 with semantic dementia (SD) and six with progressive non-fluent aphasia (PA), as
compared to 28 individuals with Alzheimer’s disease, 15 with CBS, 10 with PSP and 27 control subjects.
Different combinations of oculomotor abnormalities were identified in all clinical syndromes except for SD,
which had oculomotor performance that was indistinguishable from age-matched controls.Only PSP patients
displayed abnormalities in saccade velocity, whereas abnormalities in saccade gain were observed in
PSP`CBS `Alzheimer’s disease subjects. All patient groups except those with SD were impaired on the
anti-saccade task, however only the FTLD subjects and not Alzheimer’s disease, CBS or PSP groups, were
able to spontaneously self-correct anti-saccade errors as well as controls. Receiver operating characteristic
statistics demonstrated that oculomotor findings were superior to neuropsychological tests in differentiating
PSP from other disorders, and comparable to neuropsychological tests in differentiating the other patient
groups.These data suggest that oculomotor assessment may aid in the diagnosis of FTLD and related disorders.
Keywords: oculomotor; frontotemporal lobar degeneration; corticobasal syndrome; progressive supranuclear palsy;
Alzheimer’s disease
Abbreviations: CBD=corticobasal degeneration; CBS=corticobasal syndrome; CDR=clinical dementia rating;
FTLD=frontotemporal lobar degeneration; FTD=frontotemporal dementia; PA=progressive non-fluent apahasia;
PSP=progressive supranuclear palsy; ROC=receiver operating characteristic; SD=semantic dementia;TIV=total
intra-cranial volume;UPDRS=Unified Parkinson’s Disease Rating Scale
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Introduction
Eye movement abnormalities are sensitive markers of
neurological disease and are useful in the differential
diagnosis of a variety of clinical neurological syndromes
(Leigh and Kennard, 2004). Prominent eye movement
abnormalities have been described in corticobasal syndrome
(CBS) and progressive supranuclear palsy (PSP) (Vidailhet
et al., 1994; Rottach et al., 1996; Rivaud-Pechoux et al.,
2000), and are useful for diagnosing these disorders and
differentiating them from each other as well as other
neurodegenerative diseases (Litvan et al., 1996a, 1997; Leigh
and Riley, 2000). CBS and PSP are clinically, genetically and
pathologically related to frontotemporal lobar degeneration
(FTLD), a common cause of dementia in individuals with
disease onset at ages 565 (Boeve et al., 2003; Boxer and
Miller, 2005; Cairns et al., 2007; Kertesz et al., 2007).
However, it is not known to what extent CBS- and PSP-
related oculomotor abnormalities are present in FTLD,
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PSP or Alzheimer’s disease.
FTLD comprises three core clinical dementia syndromes,
a behavioural and dysexecutive (or frontal) variant called
frontotemporal dementia (FTD), and two forms of primary
progressive aphasia, a temporal lobe variant, also called
semantic dementia (SD), and a progressive non-fluent
apahasia (PA) (Neary et al., 1998). Diagnosis of each of the
FTLD clinical syndromes relies mainly on the identification
of a combination of progressive behavioural and neuro-
psychological impairments and the exclusion of others.
In contrast, the presence of oculomotor abnormalities is a
core diagnostic feature of PSP (Litvan et al., 1996a).
Although CBS is associated with oculomotor abnormalities
that are distinct from PSP (Leigh and Riley, 2000), such
findings do not constitute core diagnostic criteria for this
syndrome (Boeve et al., 2003). Instead, most clinical CBS
criteria rely on the presence of atypical Parkinsonism,
cortical signs and cognitive impairments. Like FTLD,
clinical research criteria for Alzheimer’s disease are
primarily based on the presence of progressive cognitive
and functional deficits (McKhann et al., 1984).
CBS and PSP display prominent visually guided saccade
abnormalities, including increased saccade latency in CBS
and decreased saccade velocity and gain in PSP (Steele
et al., 1964; Rebeiz et al., 1967; Vidailhet et al., 1994;
Rottach et al., 1996). Consistent with the overlapping
cognitive and behavioural features of CBS and PSP with
FTLD, FTLD variants with frontal lobe damage are similarly
impaired to PSP patients in their ability to withhold
visually guided (reflexive) saccades on the anti-saccade task
(Meyniel et al., 2005; Boxer et al., 2006a). Two of the core
clinical FTLD syndromes, FTD and PA, are associated with
abnormalities in voluntary saccades and smooth pursuit,
however visually guided (reflexive) saccades are relatively
normal (Boxer et al., 2006a). Increased latency, decreased
spatial accuracy and impaired ability to control the
initiation of saccades, as well as decreased smooth pursuit
gainhavebeendescribedinAlzheimer’s disease(Huttonetal.,
1984; Fletcher and Sharpe, 1986; Currie et al., 1991; Moser
et al., 1995; Shafiq-Antonacci et al., 2003; Mosimann et al.,
2004;Crawfordetal.,2005;Boxeretal.,2006a).Inthisregard,
the oculomotor abnormalities in Alzheimer’s disease are
similar to what has been described for CBS, but there have
been no direct comparisons between these disorders.
Complicating the comparison of oculomotor features
between CBS, PSP and FTLD are the overlapping molecular
pathologies identified at autopsy in all three groups. Most
clinically diagnosed cases of FTLD are found to have
protein deposits that stain for the proteins tau or ubiquitin
(FTLD-U) in different patterns (Cairns et al., 2007).
Depending on the reported pathological series, there are
approximately equal percentages of both types of molecular
pathology found at autopsy in clinically diagnosed FTD
cases (Forman et al., 2006; Josephs et al., 2006b), whereas
most SD cases are associated with FTLD-U pathology
(Davies et al., 2005). As classically described, both
corticobasal degeneration [CBD; the autopsy finding first
described in association with CBS (Rebeiz et al., 1967)] and
PSP are associated with tau deposition (in different
patterns), and most clinically diagnosed cases of PA are
also found to have CBD or PSP pathology at autopsy
(Josephs et al., 2006a). Less commonly, clinical FTD cases
may also be associated with CBD- or PSP-type pathology at
autopsy (Josephs et al., 2006b) and conversely FTLD-U
pathology may be associated with clinical oculomotor
abnormalities similar to PSP (Paviour et al., 2004). Thus,
if the clinical oculomotor features of CBS and PSP predict
tau deposition at autopsy, it would be expected that similar
oculomotor abnormalities should be detected in FTLD cases
with tau deposition, particularly PA, but also a significant
proportion of FTD cases.
The goal of this study was to directly compare the
oculomotor abnormalities associated with CBS, PSP, FTLD
and Alzheimer’s disease, and to investigate the ability of
oculomotor measurements to differentiate these syndromes.
Given the similarities between autopsy findings in CBS,
PSP and FTLD we hypothesized that the characteristic
oculomotor features of CBS and PSP would also be present
in FTLD. Since oculomotor function is less sensitive to
language or limb motor impairments than traditional
neuropsychological tests, we hypothesized that eye move-
ments would be superior to neuropsychological tests in
diagnosing the clinical syndromes with the most profound
oculomotor impairments.
Materials and Methods
Subjects
All subjects were evaluated at the University of California, San
Francisco Memory and Aging Center and gave informed consent
to participate in the experimental procedures. For demented
individuals who could not give informed consent because of their
degree of cognitive impairment, a surrogate consenting procedure
was used. First, subjects’ capacity to consent was evaluated using a
standard assessment protocol. In subjects without capacity to
consent who assented to participation, a family member or
caregiver gave consent for that subject to participate. Further
details regarding the UCSF Surrogate Consenting procedure
may be found on the UCSF Institutional Review Board (IRB)
website: http://www.research.ucsf.edu/chr/Guide/chrCogImp.asp.
All aspects of the study were approved by the UCSF IRB.
Subjects underwent neurological examination, neuropsycho-
logical testing and brain MRI scans within 3 months of eye
movement evaluation and were categorized as control, FTLD,
Alzheimer’s disease, CBS or PSP subjects. FTLD subjects met
criteria of Neary et al. (1998) for FTD, SD or PA.
Alzheimer’s disease subjects met National Institute of
Neurological and Communicative Disorders and Stroke-
Alzheimer’s Disease and Related Disorders Association criteria
for probable Alzheimer’s disease (McKhann et al., 1984). All PSP
patients met the National Institute of Neurological Disorders
and Stroke-Society for Progressive Supranuclear Palsy criteria
for probable PSP (Litvan et al., 1996a). Briefly, these include
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years or later; and (ii) vertical supranuclear gaze palsy and
prominent postural instability within the first year of disease
onset. A probable diagnosis of CBS required the following
features: (i) a slowly progressive course; (ii) asymmetric limb or
axial rigidity, present without reinforcement; (iii) aphasia,
visuospatial impairment or neglect or apraxia; and (iv) dystonia,
myoclonus, cortical sensory loss or alien limb phenomenon
(Boeve et al., 2003). To verify that CBS subjects had
Parkinsonism typical of other clinical CBS case series (Schneider
et al., 1997; Kompoliti et al., 1998; Boeve et al., 1999, 2003; Boxer
et al., 2006b), we measured Unified Parkinson’s Disease Rating
Scale (UPDRS) motor scores. As expected, CBS patients had
higher (P50.001, t-test) Unified Parkinson’s Disease Rating Scale
(UPDRS) motor scores (mean±standard deviation: 29.7±3.4;
n=9) than Alzheimer’s disease patients (3.9±2.8; n=13).
Control subjects had no neurological complaints, normal
neurological and neuropsychological examinations, and clinical
dementia rating (CDR) scores of 0 (Morris, 1993), except for one
control subject with a CDR score of 0.5 but normal performance on
neuropsychological tests. Our subject population contained 27
control, 23 FTD, 18 SD, six PA, 27 Alzheimer’s disease, 16 CBS
and nine PSP subjects. Autopsy confirmed diagnoses were available
in five FTD subjects (four FTLD-U; one Pick’s disease), five PSP
subjects (all PSP) and one PA subject (CBD) (Cairns et al., 2007).
Eye movement recordings
Subjects were seated on a cushioned chair with their heads
stabilized using padded chin and forehead rests, and a head strap.
Stimuli were viewed binocularly in a dark room, and the two-
dimensional movements of the right eye were measured using the
Fourward Technologies (Buena Vista, VA, USA) Generation 6.1
Dual Purkinje Image Eye Tracker. The spatial resolution of the
eye tracker was 1min of arc with a temporal resolution of 1ms.
The automatic optical staging (auto stage) and focus servo of the
tracker were disabled to avoid introducing head position artefacts
into the eye position data. The eye position signal was low-pass
filtered with a cut-off at 330Hz, and voltages proportional to eye
velocity were obtained by differentiating the eye position signals
with an analogue circuit. The circuit differentiated signal content
up to 25Hz and rejected signals of higher frequencies. Data were
stored for off-line analysis.
Targets consisted of white spots of 0.1  visual angle presented
on a large analogue oscilloscope (model A12-63; Xytron, Sylmar,
CA, USA) that was driven by digital-to-analogue outputs from a
digital signal processing board in a Pentium computer. The
monitor was 80cm from the subject and subtended a visual angle
of 30  horizontally by 24  vertically. The eye position signals were
calibrated at the beginning of each recording session by having
subjects fixate stationary targets at known horizontal and vertical
eccentricities.
Oculomotor paradigms
The following three paradigms were performed in all subjects and
in the same chronological sequence: prosaccades, smooth pursuit,
anti-saccades. Each paradigm was conducted as a series of trials
separated by inter-trial intervals of 1000–2000ms. The task
instructions were given by the experimenter before each of the
paradigms and subjects were asked whether they understood the
instructions. If the subject did not understand the instructions
they were repeated and demonstration trials were shown. Subjects
determined the rest period between paradigms and the overall
duration of the experiment was in the range of 30–45min.
Prosaccade trials consisted of randomly interleaved 5 and 10 
targets presented up, down, left or right of a central fixation point.
Each trial began with illumination of a central fixation spot for
1000ms. When the fixation light was extinguished, targets
appeared either immediately (overlap condition) or after a
200-ms gap (gap condition, horizontal 10  trials only). The
eccentric target remained illuminated for 1000ms. Subjects were
instructed to look at the central fixation point while it was
illuminated, then to look as quickly and as accurately as possible
at the eccentric target. At least seven responses were recorded for
each stimulus in each direction. There were no differences between
subject groups (P40.1, ANOVA) in the percentage of trials
with adequate quality data for analysis in any direction. The
mean±standard deviation percentage of analysable trials ranged
from 78.2±25% for 10  downward saccades to 84.4±20% for 10 
leftward saccades.
Smooth pursuit eye movements were evaluated in blocks of
trials that delivered step-ramp target motion (Rashbass, 1961) in
each of four directions (up, down, left or right). Each pursuit trial
began when a fixation spot was presented in the centre of the
screen for 1200–1900ms. The spot then underwent a step
displacement of 5  and a smooth ramp motion towards the
position of fixation for 600ms at 20  per second or 1200ms at 10 
per second. Subjects were instructed to follow the target as
accurately as possible. Each target was presented 10–15 times.
Anti-saccade trials began with the illumination of the central
fixation point for 1000ms. The central fixation point was then
replaced by a minus sign for 1000ms. After a 200-ms gap, targets
appeared 10  to the right or left and remained illuminated for
1000ms. Subjects were given instructions to ‘look away from the
target that appears on the side at the corresponding spot on the
other side of the fixation point, and if you make a mistake try to
correct yourself.’ The minus sign before the appearance of the
lateral target served as a reminder to look in the direction
opposite to the target stimulus. Responses to at least 18 anti-
saccade trials were recorded in each direction. There were no
differences (P40.05, ANOVA) in the percentage of analysable
anti-saccade trials between subject groups.
Data analysis
All data were analysed interactively offline. For saccades, a cursor
was moved along each individual trial and the following marks
were made: (i) the point in position and time where the saccade
began; (ii) the point in position and time where the first eye
movement ended; and (iii) the final eye position. Saccade latencies
were computed as the duration of the interval from the
appearance of an eccentric target to the onset of the first eye
movement. Saccade first gains were computed as the difference in
eye position between fixation and the end of the first movement.
Sacccade end gains were computed as the difference in eye
position between fixation and the final eye position for the trial.
To minimize the contribution of lens shift artefacts from the
Purkinje tracker (Deubel and Bridgeman, 1995), mean saccadic
velocity was estimated as the initial change in eye position (first
gain) divided by the duration of the initial saccade. Analysis of
selected data showed the same effects, but higher values, in
measurements of peak eye velocity obtained by differentiation
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and/or amplitude below 1  were rejected.
Data analysis for pursuit trials began with the removal of rapid
deflections (due to saccades) from the eye velocity traces. A cursor
was movedalong each eye velocity trace andthe start and end of each
rapid deflection was marked. These deflections were then excised
and the intervening velocity points were estimated using a linear
interpolation algorithm. The responses to identical stimuli were
aligned on the onset of target motion and the mean and standard
deviation of eye velocity were calculated at each sample point.
The mean eye velocity responses were used to estimate latency,
initial eye acceleration and two estimates of gain for each target
direction. The latency to onset of pursuit was defined as the time
at which the amplitude of eye velocity was 43 SD from the
baseline velocity during fixation. The average eye acceleration for
the first 100ms of pursuit was determined by calculating the
difference between eye velocity 100ms after pursuit onset and eye
velocity at the initiation of pursuit, divided by 100ms. Peak gain
was computed as the average of 10 points either side of the
maximum eye velocity divided by the target speed. Finally, we
calculated the mean gain as the average eye velocity for the period
the target was moving divided by the target speed.
Anti-saccades were marked in a similar way to prosaccades.
A cursor was moved along each trial and three points were
marked: (i) the point in position and time where the saccade
began; (ii) the position where the first eye movement ended; and
(iii) the final eye position. Responses were considered to be
successful anti-saccades if the first eye movement after target onset
had an amplitude43  and was in the opposite direction from the
target. Anti-saccade corrections were recorded as anti-saccades
that occurred within 500ms of the initial erroneous prosaccade.
Neuropsychological battery
Subjects were administered a comprehensive neuropsychological
battery that measures multiple domains of cognition (Table 1).
Tests of general cognition and functional abilities included the
Mini-Mental State Examination (MMSE) (Folstein et al., 1975)
and the CDR (Morris, 1993). Verbal memory was evaluated using
the California Verbal Learning Test – Mental Status (CVLT-MS)
(Delis et al., 2000) (total of trials one through four and the
10-min delayed recall trial). Visual memory was assessed using the
30-min delayed recall trial of the Wechsler Memory Scale – Visual
Reproductions (Wechsler, 1997). The longest correct backward
digit span (Wechsler, 1997) was used as a measure of working
memory. Language was assessed using a 15-item Boston Naming
Test (Kaplan et al., 1983), and measures of verbal fluency included
phonemic fluency (number of D words in 1min) and category
Table 1 Demographic and neuropsychological results
Controls FTD SD PA AD CBS PSP
Demographics
n 27 24 19 6 28 15 10
Age 65.0 1.5 57.4   1.7 60.3 1.3 64.5 3.0 59.8 1.4 62.7   2.0 65.5   1.3
Duration (years) ^ 4.2 1.0 5.3 0.7 4.8 0.5 4.7 0.5 3.4   0.4 3.3   0.6
Gender (m/f) 10/17 16/8 10/9 1/5 17/11 6/9 8/2
Education 17.2   0.5 19.1   3.5 15.9   0.7 16.3   1.2 15  0 .6 1 4. 9 0 .7 1 6.8 1 . 1
General
MMSE 29.7   0.4 23.5 7 .5 2 1 . 7 7 .3 25.2 3.5 19.5   5.3 19.8   7.7 26.8 2.6
CDR total 0.0   0.1 1.1   0.4 0.8   0.3 0.5   0.3 0.8 0.2 0.9 0.6 1.2 0.5
CDR box score 0.5  0.1 6.6 2.4 4.5 2.1 1.9   1.4 5 . 4 1 .5 4. 9 3. 4 6.8 2. 1
Memory
CVLT trials 1^4 (max. 36) 29.9 4.3 18.8   9.1 13.1   9.4 22.0 7 .9 13.8   5.2 14.9   7.0 22.7 4.1
CVLT10’ recall (max. 9) 7 .6 1.8 3.6 3.1 1.8 2.7 5.8   1.2 1.1   1.4 3.1   3.1 5.3   1.2
WMS Vis recall (scaled) 14.5 2.9 7.7   4.0 7.4   3.6 11.6   4.9 4.3   1.5 6.6   3.7 9.4   1.1
Mod. Rey recall (max.17) 13.3 0.5 7. 5   1.2 8.0   1.3 12.0   0.3 2. 9 0. 7 5. 4 1 . 4 7 . 9 0.5
Language
BNT( max.1 5) 1 4 .6 0 .7 1 1 .7 4 . 4 4.1 4.8 11.0   1.5 1 1 .2 3.6 1 0. 7 5 .2 11.3   5.0
Animals/min. 24.1 5.3 12.6 7.3 6.2 5.7 8.0 3.7 8.2 4.7 10.2 5.7 9.9 3.0
D-words/min. 15.2 4.1 8.4 5.9 7.3 8.6 5.3 4.3 7.8 6.7 7.9 4.2 5.9 1.8
Visuospatial
V OSP( max.1 0) 9 .3 1 . 0 7 .7 2.2 9 .7 0 .5 1 0 . 0 0 . 0 5.6  2.8 5.4   3.6 7.1   2 .0
Beerycop y( max.1 6) 1 5 . 0 1 . 0 1 2.8 2.8 1 4.7 1.5 12.2   4.2 7.0   5.5 5.8   5. 2 9.5   3.2
Block Design 12.7 2.8 8.2 4.1 10.6   3.4 9.5   1.3 4.0 3.4 4.6 3.5 5.9 2.1
Mod .R e ycop y( max.1 7) 1 6.3 0 . 1 1 4.8 0 .7 1 6. 0 0 .3 1 4.2 2.3 8.4 1.2 8.1 1.7 11.8 0.7
Executive
Digits backward 5.4 1.3 3.6 1.4 4.6 1.5 2.8 0.8 3.0 1.3 2.6 1.3 3.1 0.8
Stroop interference (scaled) 12.3 1.4 6. 1 4.6 6.5 4. 4 1 .5 0. 7 1 .8 1 .6 4. 1 3. 7 2. 7 2. 4
Trails (lines/min) 33.9 12.9 32.2 63.7 24.9 13.8 17 .0 16.0 4.4 6.9 4.3 5.3 4.8 2.4
Bold values indicate P50 . 0 5v s .c o n t r o l ,A N O V Aw i t hT u k e ypost hoc.FTD=Frontotemporal dementia; SD=semantic dementia;
PA=progressive nonfluent aphasia; AD=Alzheimer’s disease; CBS=corticobasal syndrome; PSP=progressive supranuclear palsy;
MMSE=Mini Mental State Exam; CDR=Clinical Dementia Rating; CVLT=CaliforniaVerbal LearningTest; WMS=Wechsler Memory
Scale; BNT=modified Boston NamingTest; VOSP=Visual Object Spatial Perception battery.
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condition from the Visual Object Spatial Perception battery
(VOSP) (Warrington and James, 1991), the WAIS-III
Block Design (Wechsler, 1997) and a modified Beery Test of
Visual-Motor Integration (Beery, 1997), which requires subjects
to copy eight figures, and copy of a simplified version of the
Rey–Osterrieth figure, were used to assess visuospatial abilities.
Executive function was assessed using Stroop (Interference
condition, scaled score) from the Delis–Kaplan Executive
Function System (D-KEFS) (Delis et al., 2001) and a modified
Trailmaking test (number of correct lines per minute) (Kramer
et al., 2003).
Lobar brain volumes
MRI scans were obtained on a 1.5-T Magnetom VISION system
(Siemens Inc., Iselin, NJ, USA) at the San Francisco VA Magnetic
Resonance Unit, as described in a previous report (Rosen et al.,
2002). 3D T1-weighted scans (MP-RAGE) were used for generat-
ing lobar volumes. Lobar volumes were generated using the
BRAINS2 software package [Mental Health – Clinical Research
Center at the University of Iowa (Magnotta et al., 2002)]. Briefly,
the T1-weighted images were spatially normalized so that the
inter-hemispheric fissure was aligned vertically in the axial and
coronal views and the line connecting the anterior and posterior
commissures was horizontal in the sagital view, and re-sampled to
1.0mm
3 voxels. Next, the outermost boundaries of the cortex, as
well as the anterior and posterior commissure, were identified to
warp the Talairach grid (Tailarach and Tournoux, 1988) onto the
current brain. The T2- and PD-weighted images were then
realigned to the spatially normalized T1-weighted image using an
automated image registration programme (Woods et al., 1992).
A brain mask was generated using a previously trained artificial
neural network, and lobar volumes were then calculated using
an automated Talairach-based method of regional classification
(Magnotta et al., 2002). Finally, the lobar volumes were normal-
ized to correct for differences in overall head size: the absolute
lobar volume was multiplied by the average total intra-
cranial volume (TIV) of all subjects and then divided by the
individual’s TIV.
Statistics
In the first stage of our analysis, we compared demographic,
neuropsychological and eye movement measures between diag-
nostic groups using chi-square tests for categorical measures and
ANOVA with Tukey post hoc statistics for continuous measures.
In the second stage of our analysis, we identified the single eye
movement or neuropsychological measure that best distinguished
between pairs of diagnostic groups using recursive partitioning
(classification and regression trees) (Breiman et al., 1984).
We focused on single variables since many of the diagnostic
groups were small and the initial trees contained just a single split.
The recursive partitioning analyses identified the single variables
that minimized misclassification between groups. We identified
the single ‘best’ oculomotor and neuropsychological variables and
constructed receiver operating characteristic (ROC) curves
(Hanley and McNeil, 1982) to assess their ability to differentiate
groups of interest. We measured the area under each ROC curve
and compared them using chi square statistics (DeLong et al.,
1988). These comparisons assessed whether the ‘best’ oculomotor
and neuropsychological variables differed in their ability to
differentiate the groups.
For all tests, significance was accepted at the P50.05 level.
We carried out the statistical analyses using routines in SPSS
(version 14.0, Chicago, IL, USA), Stata (version 10, College
Station, TX, USA) and R (R Development Core Team. 1999. R: A
language and environment).
Results
Demographics
The FTD patient group was significantly younger than the
control group (P=0.01), but there was no significant
difference in age between the patient groups (Table 1).
There was also no significant difference in disease duration,
gender or education between patient groups. All patients,
except the PA group, were significantly different from
controls on the CDR total score and sum of boxes score
(P50.001). Mean MMSE scores were lower in FTD, SD,
Alzheimer’s disease and CBS groups than controls
(P50.001), however, there were no significant differences
in MMSE score between controls, PA and PSP patients.
Memory
Short-term memory impairments were observed in all
patient groups relative to controls. The FTD, SD,
Alzheimer’s disease and CBS groups had lower scores on
both the California Verbal Learning Test (CVLT) learning
and delayed recall trials than controls (P50.001 for both).
Alzheimer’s disease individuals also recalled fewer words
after the 10-min delay than FTD, PA and PSP subjects
(P50.02). All patient groups except PA scored lower
relative to controls on recall of the Wechsler Memory
Scale visual reproductions (P50.011). Alzheimer’s disease
individuals were more impaired on this measure than all
other patients (P50.045) except CBS (P=0.311).
Language
All patient groups were significantly impaired on language
measures relative to controls. SD, Alzheimer’s disease and
CBS individuals scored lower (P50.05) relative to controls
on a 15-item version of the Boston Naming Test (BNT).
SD patients named fewer pictures than all other subject
groups on the BNT (P50.004). Verbal fluency measures
(D-words or animals per minute) were impaired in all
patient groups relative to controls (P50.001 for animals,
P50.04 for D-words).
Visuospatial function
Visuospatial function was most impaired in Alzheimer’s
disease and CBS. Both groups had lower scores relative to
controls on the number location task from the Visual
Object Spatial Perception (VOSP) test (P50.001), modified
Rey–Osterrieth figure copy (P50.01) and copy of the Beery
Visual Motor Integration figures (P50.04). Other patient
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controls on these measures. On the WAIS-III block design
task, the FTD, Alzheimer’s disease, CBS and PSP groups
had lower performance relative to controls (P50.011).
Executive function
Backward digit span was reduced in all patient groups
except SD relative to controls (P50.003). Performance on
the Stroop interference task was impaired in all patient
groups relative to controls (P50.003), however only the
Alzheimer’s disease and CBS subjects generated fewer lines
than controls on the D-KEFS Trails (P50.021).
Visually guided saccades
Examples of three successive upward, 10  saccades from a
representative subject from each patient group are shown in
Fig. 1. As a group, SD and PA patients showed no deficits
in visually guided (pro-) saccades to single targets as
compared to controls (Fig. 2). As compared to controls,
FTD patients displayed mildly hypometric saccades, that is
the gains of the first saccade towards targets that appeared
5  up or down or 10  left or right of the central fixation
point were smaller (P=0.013 for vertical 5  overlap,
P=0.038 for horizontal 10  gap; Supplementary Tables S1
and S2).
Alzheimer’s disease patients showed increased latency of
all saccades compared to controls (P=0.001 for horizontal
10  overlap, P50.001 for vertical 10  overlap, P=0.002 for
horizontal 5  overlap, P50.001 for vertical 5  overlap,
P=0.047 for horizontal 10  gap). Vertical saccade latency
was also increased as compared to FTD and SD patients
(P50.04). Vertical, but not horizontal saccades were
hypometric relative to controls (P=0.028).
Like Alzheimer’s disease patients, CBS individuals
displayed increased saccade latencies in the vertical
(P50.001) direction and a trend towards increased latency
in the horizontal (P=0.067) direction as compared to
controls. There was a decrease in the first gain of vertical
saccades to 5  and 10  targets compared to controls and all
patient groups (P50.015) except PSP patients who had
lower vertical saccade gains than CBS.
Of all the patient groups, PSP subjects’ saccades were the
most different from controls and showed abnormalities in
almost all aspects of visually guided saccade function.
In these individuals, latency for vertical 10  and 5  saccades
was increased compared to controls (P50.001), FTD and
SD patients (P50.003).
PSP patients displayed dramatically decreased saccade
velocity as compared to controls (P50.001) and all other
patient groups (P50.007) for 10  saccades. In the 5 
horizontal condition, differences in velocity only reached
significance as compared to SD, Alzheimer’s disease and
CBS patient groups (Supplementary Table S2). First gains
were reduced for all saccades in PSP patients compared
to controls and other patient groups (P50.001 for all).
The end gain was also decreased compared to controls for
horizontal and vertical 10  overlap and vertical 5  overlap
saccades (P=0.001 for horizontal 10  overlap, P50.001 for
vertical 10  overlap, P50.001 for vertical 5  overlap). End
gain for horizontal and vertical 10  overlap and vertical 5 
overlap saccades was also decreased compared to all other
patient groups (except horizontal 10  overlap saccades
compared to PA patients).
Smooth pursuit
Smooth pursuit of step-ramp targets (Rashbass, 1961;
Rottach et al., 1996) travelling at 10 or 20  per second
was impaired in the Alzheimer’s disease, FTD and PSP
patient groups. Mean vertical pursuit traces for a target
moving upward at 20  per second from representative
Fig. 1 Upward saccade examples. Eye position versus time traces showing three representative, successive10  upward saccades in a
control subject and a patient from each of the diagnostic groups.
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there was a non-significant trend towards lower initial
acceleration of smooth pursuit in the vertical direction
(P=0.057). There were no significant smooth pursuit
abnormalities in the SD and PA patients for horizontal
and vertical smooth pursuit targets moving at 20  per
second and 10  per second (Fig. 4, Supplementary
Tables S3 and S4).
FTD patients displayed multiple abnormalities in hori-
zontal 20  per second pursuit compared to controls.
Compared to controls the FTD group had reduced mean
and peak gains and initial acceleration (P=0.008 for mean
gain, P 0.004 for peak gain, P 0.044 for initial acceleration).
Mean and peak gains were also reduced in the FTD group
compared to the SD group for horizontal pursuit targets at
20  per second.
Alzheimer’s disease patients had impaired pursuit
compared to controls and SD patients. Latency was
increased for targets moving vertically at 10  per second
(P=0.013) and mean and peak gains were reduced in
Alzheimer’s disease subjects compared to controls for
horizontal and vertical targets moving at 20  per second
(peak gain P50.01 for horizontal; P50.02 for vertical).
Mean and peak gains were also reduced in Alzheimer’s
disease patients compared to SD patients for horizontal and
Fig. 2 Bar graphs summarizing the saccade behaviour under overlap conditions of controls (CON) and all the patient groups.Targets
moved10 . In all graphs, black and grey bars show responses to horizontal and vertical targets respectively. Error bars show standard
errors across subjects within each group. Asterisks indicate effects that were statistically significantrelative to controls (P50.05, ANOVA,
Tukey post hoc). Double asterisks indicate P50.005 relative to controls. (A) Saccade latencies, (B) Saccade slope velocity, (C)F i r s tg a i no f
saccades, (D) End gain of saccades.
Fig. 3 Average vertical eye velocity traces for a control subject
and a patient from each of the diagnostic groups.Target motion
was 20 /s upward.Traces are an average of at least eight trials.
1274 Brain (2008),131,1268^1281 S.Garbutt et al.vertical targets at 20  per second (except peak gain to a 20 
per second vertically moving target). Initial acceleration was
reduced in Alzheimer’s disease patients in all directions and
at both target speeds (P50.003 for horizontal; P50.005 for
vertical 10 and 20  per second pursuit). Initial acceleration
in Alzheimer’s disease patients was lower than SD patients
for 20  per second horizontal and vertical pursuit and 10 
per second vertical pursuit (P50.05).
As with saccades, smooth pursuit deficits were most
severe in PSP patients. Compared to controls, PSP patients
had longer latencies to horizontal and vertical 20  per
second targets and horizontal 10  per second targets
(P=0.001 for horizontal and vertical 20  per second
pursuit, P=0.003 for horizontal 10  per second pursuit).
Between patient groups, PSP patients had longer latencies
to initiation of pursuit to horizontal 20  per second targets
than FTD and SD patients and longer latencies to vertical
20  per second targets than FTD, SD and PA patients.
Compared to controls and SD patients, the mean and peak
gains of pursuit to horizontal targets moving at 20  per
second and 10  per second were reduced in PSP patients
(mean gain P=0.002, peak gain P=0.003 for 20  per
second horizontal pursuit; mean gain P=0.001, peak
gain P50.001 for 10  per second horizontal pursuit).
Initial acceleration in PSP patients was reduced horizontally
and vertically to both target speeds in PSP patients
compared to controls (P=0.040 for 20  per second
horizontal targets, P=0.010 for 20  per second vertical
targets, P=0.001 for 10  per second horizontal targets,
P=0.034 for 10  per second vertical targets). The initial
acceleration of PSP patients was also reduced compared to
SD patients.
Anti-saccades
The anti-saccade task requires a subject to suppress a
visually guided saccade to an eccentrically appearing target,
and instead generate a saccade in the opposite direction.
FTD, PA, Alzheimer’s disease, CBS and PSP patients all
made fewer correct anti-saccades compared to controls
(P50.001 for FTD, Alzheimer’s disease, CBS and PSP
patients, P=0.020 for PA patients) (Fig. 5). Anti-saccade
responses in SD patients were not significantly different
from controls. FTD, Alzheimer’s disease, CBS and PSP
patients also made significantly fewer correct responses than
SD patients (P50.001 for Alzheimer’s disease, CBD and
PSP patients; P=0.018 for FTD patients). PSP patients
generated the fewest correct anti-saccade responses, and in
Fig. 4 Bar graphs summarizing the pursuit behavior of controls (CON) and all the patient groups.Target velocity was 20 /s. In all
graphs, black and grey bars show responses to horizontal and vertical targets respectively. Error bars show SEs across subjects
within each group. Asterisks indicate effects that were statistically significant relative to controls (P50.05 ANOVA, Tukey post hoc).
Double asterisks indicate P50.005 relative to controls. (A) Smooth pursuit latencies, (B) Initial eye acceleration of smooth pursuit,
(C) Mean gain of smooth pursuit, (D) Peak gain of smooth pursuit.
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this group also made fewer correct responses compared
to FTD patients (P=0.022). There were no differences
in anti-saccade latencies between any of the groups
(Supplementary Table S5).
All the patient groups were able to spontaneously correct
a proportion of anti-saccade errors indicating that the
subjects understood the task. However, Alzheimer’s disease,
CBS and PSP patients corrected a lower proportion of
errors as compared to controls (P50.001 for Alzheimer’s
disease and CBS patient groups, P=0.004 for PSP patients).
Alzheimer’s disease patients corrected the lowest proportion
of errors and the proportion of errors corrected in these
patients was smaller than in FTD, SD and PA patients
(P50.05). The addition of self-corrected errors to the
percentage of correct anti-saccade responses in each group
did not alter the differences in anti-saccade performance
between groups.
Comparison of neuropsychological and
oculomotor variables for group
differentiation
Table 2 summarizes the differences in oculomotor perfor-
mance between each of the patient groups and the normal
control subjects as identified using ANOVA. To identify
which of these oculomotor abnormalities were most
valuable for differentiating the patient groups, we con-
structed nine binary diagnostic comparisons involving the
CBS, PSP, FTD, Alzheimer’s disease and SD groups based
on common diagnostic dilemmas encountered in the
clinic (Table 3). The best single oculomotor and neuro-
psychological variables for each comparison were identified
using recursive partitioning (classification and regression
trees), a non-parametric, multivariate method. Separate
trees were constructed for oculomotor and neuropsycho-
logical variables. The best variables were then plotted on
the same ROC curve and the area under the curve (AUC)
values were directly compared to assess whether
one measure was superior to the other for differentiating
the groups.
Figure 6 shows examples of ROC curves for the
differentiation of PSP subjects from all other patients, and
the SD patients from the Alzheimer’s disease patients. For
the PSP versus all other patients differential (Fig. 6A), the
comparison of AUCs revealed that the best oculomotor
measure (upward 10  saccade velocity) was superior to the
best neuropsychological measurement (Trails time) in
differentiating the two groups (P50.0001, Chi Square;
Table 3). In contrast, examination of AUC values for the
SD versus Alzheimer’s disease comparison (Fig. 6B)
revealed that the best oculomotor variable (the percentage
of correct anti-saccade responses with self corrected errors)
was similar to the best neuropsychological variable (the
VOSP score) in terms of ability to distinguish these two
diagnosticgroups(P=0.518;Table3).Forallotherdiagnostic
comparisons, oculomotor performance was similar to
neuropsychological tests in differentiating subject groups.
Comparison of CBS and Alzheimer’s
disease groups
Both the Alzheimer’s disease and CBS groups had markedly
elevated saccade latencies and obtained lower scores relative
to controls on all neuropsychological measurements of
visuospatial function, including the Beery Figure Copy,
modified Rey–Osterrieth figure copy and VOSP number
localization task (Table 1). Since both Alzheimer’s disease
(Thompson et al., 2003; Boxer et al., 2003b;D uet al., 2007)
and CBS (Groschel et al., 2004; Boxer et al., 2006b) are
associated with damage to extra-striate visual cortical
Fig. 5 Bar graphs summarizing the antisaccade behavior of
controls (CON) and all the patient groups. In all graphs the bars
show the responses to horizontal targets and the error bars
show standard errors across subjects within each group.
Asterisks indicate effects that were statistically significant relative
to controls (P50.05, ANOVA, Tukey post hoc). Double asterisks
indicate P50.005 relative to controls. (A) Percentage of correct
antisaccades, (B) Percentage of errors that were corrected
which was calculated by: number of trials that were corrected/
number of error trials 100.
1276 Brain (2008),131,1268^1281 S.Garbutt et al.structures and visuospatial function is correlated with brain
volume in the extra-striate cortical regions in Alzheimer’s
disease (Boxer et al., 2003a), we hypothesized that saccade
latency may also be correlated with atrophy of visual
cortical regions, regardless of clinical syndrome. To test this
hypothesis, lobar (frontal, temporal, parietal and occipital)
brain volumes, corrected for total intra-cranial volume to
control for differences in head size, were correlated with
Fig. 6 Receiver operating characteristic (ROC) curves comparing best oculomotor and neuropsychological variables. (A) Comparison of
the best oculomotor variable from the recursive partitioning analysis (upward saccade velocity) versus the best neuropsychological variable
(time to complete the modified trails task) for differentiating PSP from all other patients. (B) Comparison of the best oculomotor variable
(percentage correct antisaccade responses) versus best neuropsychological variable (number localization task fromVOSP battery) for
differentiating SD from AD group.
Table 2 Summary of oculomotor abnormalities by patient group
Horizontal
saccades
Vertical
saccades
Horizontal
pursuit
Vertical
pursuit
Antisaccade
correct responses
Antisaccade spontaneous
error correction
FTD # First gain NS ## Gain # Acceleration ## NS
## Acceleration
SD NS NS NS NS NS NS
PA NS NS NS NS ## NS
AD "" Latency "" Latency ## Gain " Latency ## ##
# First gain ## Acceleration ## Gain
## Acceleration
CBS " Latency "" Latency ## Gain " Latency ## ##
# First gain ## End gain ## Acceleration ## Acceleration
PSP # First gain "" Latency "" Latency "" Latency ## ##
## Velocity ## Gain ## Gain # Gain
## Velocity ## Acceleration ## Acceleration
NS=not significantly different from controls; #=mildly decreased compared to controls; ##=moderate-severely decreased; "=m i ld l y
increased; ""=moderate-severely increased.
Table 3 Comparison of oculomotor and neuropsychological variable for group differentiation
Comparison Oculomotor Neuropsychology Comparison
Model AUC Model AUC 
2 P
PSP vs. Not PSP Upward saccade velocity (10deg) 1.0 Trails time 0.78 30.1 50.0001
PSP vs. CBS Horizontal saccade gain (10deg) 1.0 Trails correct 0.83 3.9 0.048
PSP vs.FTD Horizontal saccade gain (10deg) 0.99 Modified Rey copy 0.85 3.65 0.056
SD vs. AD Antisaccade correct+corrections 0.89 VOSP 0.94 0.42 0.518
SD vs. Not SD Antisaccade correct+corrections 0.80 BNT 0.83 0.39 0.532
CBSvs. AD Down saccade velocity (10deg) 0.76 CVLTrecall 0.64 1.24 0.266
FTD vs. SD Antisaccade correct responses 0.74 BNT 0.84 0.66 0.265
CBSvs. Not CBS Antisaccade correct+corrections 0.73 Beery 0.76 0.13 0.717
FTD vs. Not FTD Vertical saccade latency (10deg) 0.64 Trails correct 0.72 0.67 0.415
AUC=Area under curve from receiver operating characteristic (ROC) curve analysis; ‘Not’ refers to all other patients (no controls),
see legend toTable 1 for additional abbreviations.
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vertical and anti-saccade latencies. As expected, the
Alzheimer’s disease and CBS groups had smaller parietal
and occipital lobe volumes than the control and SD groups
(Table 4), and correlations were identified for the three
visually guided saccade variables, but not for anti-saccade
latency (Table 5). As predicted, the strongest correlations
between saccade latency and brain volume were observed in
the visual cortical regions, including the bilateral parietal
and occipital lobes and right temporal lobe. No correlations
were identified between frontal cortex volume and saccade
latency.
Discussion
We directly compared horizontal and vertical oculomotor
performance in three FTLD clinical syndromes, Alzheimer’s
disease, CBS and PSP and evaluated the ability of
oculomotor findings to differentiate patient groups.
Significant oculomotor abnormalities were identified in all
patient groups except for SD, which had oculomotor
performance that was indistinguishable from age-matched
controls. In all subjects, both visually guided saccade and
smooth pursuit abnormalities were more prominent in the
vertical than horizontal plane. Only PSP patients displayed
abnormalities in saccade velocity, whereas abnormalities in
saccade gain were observed in PSP4CBS4Alzheimer’s
disease subjects. All patient groups except SD were
impaired on the anti-saccade task, however only the
FTLD (FTD, SD and PA) subjects and not Alzheimer’s
disease, CBS and PSP, were able to spontaneously self-
correct erroneous prosaccades as well as controls. ROC
statistics revealed that oculomotor assessments were super-
ior to neuropsychological tests for differentiating PSP from
other diagnoses, and comparable to neuropsychological
tests in differentiating the other patient groups. These data
suggest that oculomotor assessments, particularly of vertical
saccades and anti-saccades, may be useful for the differ-
ential diagnosis of clinical dementia syndromes.
Diagnostic value of clinical oculomotor
abnormalities
Multiple oculomotor abnormalities were identified in all of
the patient groups except PA and SD. However, measure-
ments of vertical and horizontal saccade velocity and gain
as well as the percentage of correct anti-saccade responses
were most useful for differentiating the patient groups
(Fig. 6 and Table 3).The most dramatic oculomotor
impairments were observed in PSP, involving almost all
aspects of saccade and smooth pursuit function. In this
respect, our findings are similar to previously published
descriptions of PSP-associated oculomotor abnormalities.
(Vidailhet et al., 1994; Rottach et al., 1996; Rivaud-Pechoux
et al., 2000) Unlike these reports, we found increased
latency of saccade initiation in the vertical plane in our PSP
Table 4 Mean regional brain volumes
L Frontal R Frontal LTemporal R Temporal L Parietal R Parietal L Occipital R Occipital
Cont rol 1 80 .2 1 7 .7 1 89 .5 1 7 . 4 1 06. 0 6. 0 1 06. 9 4.7 1 1 0 . 4 1 0 .3 1 1 3 .7 9 .8 52. 9 6. 1 5 1 .8 4.2
FTD 1 58.3 2 1 .6 1 64.2 23 . 4 1 02.2 9 . 4 99 . 1 1 2. 6 1 06. 4 7 . 9 1 06. 4 8. 6 55 .8 5 .2 49 .7 4.7
S D 1 64 . 4 1 8. 9 1 86. 4 1 4.7 82.7 1 1 .5 96.6 8. 9 1 04. 9 7 . 4 1 1 3 . 9 8. 1 5 1 . 4 5 . 0 50 . 4 5 . 4
PA 153.0   11.6 173.0   10.7 100.5   11.3 105.1   6.9 99.8   10.4 107.9   10.6 51.5   5.2 50.7   5.9
AD 167.0   17.2 178.3   13.4 98.7   8.6 100.4   6.8 97.2   10.3 100.1   9.2 48.2   5.1 46.0   4.8
CBS 158.2  12.6 169.7   16.0 95.3   7.6 96.5  5.9 99.2  5.9 99.0   9.4 51.0   3.9 46.2  4.5
PSP 1 77 .2 1 3 .8 1 85 .3 1 3 .8 1 04 . 4 6.5 1 02. 4 7 . 0 1 08.8 9 . 0 1 09 .2 8.5 5 3 . 9 5 .2 49 . 6 6. 4
P50.05 AD5Con AD5Con
Tukey post hoc FTD5Con FTD5Con SD5All SD5Con CBS5Con CBS5Con
PA5Con FTD5SD CBS5Con CBS5Con AD5SD AD5SD AD5SD CBS5Con
CBS5Con FTD5PSP AD5PSP CBS5SD AD5Con
Mean SD lobar brain volumes (normalized to total intracranial volume) for each subject group. Group ANOVA values were significant
(P50.02) for all brain regions.Group differences identified using aTukey post hoc analysis are shown in the bottom panel.
Table 5 Saccade latencyçbrain volume correlations
L Frontal R Frontal LTemporal R Temporal L Parietal R Parietal L Occipital R Occipital
Horizontal latency 0.024  0.108  0.091  0.307    0.229   0.279   0.430    0.282 
Horizontal latency (gap)  0.010  0.101  0.192  0.321    0.256   0.256   0.419    0.221 
Vertical latency 0.041  0.082  0.019  0.146  0.182  0.267   0.355    0.277 
Antisaccade latency 0.041 0.054  0.144  0.131  0.097  0.082  0.135  0.042
Pearson correlation coefficients are shown for the relationship of mean 10 degree saccade latencies to lobar brain volumes (normalized to
total intracranial volume).  P50.05,   P50.005 (n=90) .
1278 Brain (2008),131,1268^1281 S.Garbutt et al.subjects. This increased latency might be explained by
differences in the definition of saccade onset used here as
opposed to other studies. Consistent with the central role of
oculomotor abnormalities in the diagnosis of PSP, the
vertical saccade gain and velocity (data not shown)
measurements were superior to neuropsychological tests
for differentiating these patients from CBS, FTD and the
other patient groups.
Importantly, the lack of measurable oculomotor
impairments in the SD group was useful for differentiating
these patients from other patient groups, particularly
the Alzheimer’s disease subjects who had similar neurop-
sychological deficits to the SD subjects in most cognitive
domains (aside from visuospatial function). Normal
performance on the anti-saccade task was able to differ-
entiate SD patients from Alzheimer’s disease, FTD and the
other patient groups, particularly when the percentage of
self-corrected errors was included in the anti-saccade score
(Fig. 6).
Although oculomotor and neuropsychological values
were similar in CBS and Alzheimer’s disease, downward
saccade velocities were able to differentiate the CBS from
the Alzheimer’s disease subjects (Table 3). Both Alzheimer’s
disease and CBS patients had increased latency of saccades,
prominent impairments in smooth pursuit and impaired
performance on the anti-saccade task relative to controls.
These results are consistent with previous descriptions of
oculomotor abnormalities in Alzheimer’s disease (Hutton
et al., 1984; Fletcher and Sharpe, 1986; Currie et al., 1991;
Moser et al., 1995; Abel et al., 2002; Shafiq-Antonacci et al.,
2003; Crawford et al., 2005; Boxer et al., 2006a) and CBS
(Vidailhet et al., 1994; Rottach et al., 1996; Rivaud-Pechoux
et al., 2000, 2007). The fact that the increased saccade
latency in our series was less prominent than that
previously reported (Rivaud-Pechoux et al., 2000) for CBS
may have reflected differences in the visually guided saccade
paradigm that we used. We measured saccades to 5 and 10 
targets, whereas others studied larger amplitude
saccades (25 ).
Oculomotor impairments were also able to differentiate
FTD from other patient groups, but there was a non-
significant trend towards better diagnostic differentiation of
FTD patients using neuropsychological measures than
oculomotor variables. FTD patients displayed slightly
hypometric horizontal saccades but were otherwise similar
to controls in their ability to perform visually guided
saccades. As compared to controls, FTD patients had
decreased gain and initial acceleration of horizontal
pursuit as well as decreased vertical pursuit acceleration.
FTD patients were impaired in their ability to withhold a
visually guided saccade on the anti-saccade task, but were
not significantly impaired relative to controls in the
frequency with which they self-corrected erroneous prosac-
cades on the anti-saccade task. These results are consistent
with previous studies of anti-saccade abnormalities in FTD
as compared to PSP (Meyniel et al., 2005), as well as
saccade and smooth pursuit abnormalities in FTD as
compared to other FTLD subtypes and Alzheimer’s disease
(Boxer et al., 2006a).
Clinical and anatomical correlates of
oculomotor impairments
Our findings suggest that oculomotor impairments reflect
the anatomical patterns of brain damage associated with
neurodegenerative syndromes. The patient groups that were
found to have brain atrophy involving the frontal and
parietal lobes (FTD, PA, Alzheimer’s disease and CBS in
Table 2) which contain the frontal and parietal eye fields
(Pierrot-Deseilligny et al., 2004) displayed deficits in the
initiation and suppression of saccades and smooth pursuit,
but normal saccade velocities. PSP subjects, who have
prominent atrophy of the brainstem oculomotor regions,
(Groschel et al., 2004; Boxer et al., 2006b) displayed
additional deficits in saccade velocity and end gain.
In contrast, SD patients had no measurable differences in
oculomotor function from controls, despite having cogni-
tive impairments that were comparable to the other patient
groups (Table 1) and prominent atrophy that spared the
frontal and parietal lobes (Table 4). Oculomotor impair-
ments, including increased saccade latency and a reduced
ability to self-correct anti-saccade errors were most similar
in Alzheimer’s disease and CBS, the two clinical syndromes
that were also found to have volume loss in the parietal and
occipital lobes (Table 4). Consistent with these findings,
visually guided saccade latencies, which were prominently
increased in these groups, correlated with parietal and
occipital lobe volumes (Table 5). The correlation between
saccade latency and volume of visual cortical regions is
similar to focal lesion studies from stroke patients which
have demonstrated increased saccade latency with lesions
involving the right parietal lobe (Pierrot-Deseilligny et al.,
1991). Although we did not identify a correlation between
anti-saccade latency and lobar brain volume a previous
study demonstrated correlations between regional frontal
lobe grey matter volume and anti-saccade performance in
FTLD and Alzheimer’s disease (Boxer et al., 2006a)
suggesting that other structural neuroimaging methods
might be more sensitive to oculomotor function–brain
volume correlations than those used here.
A limitation of this study was that the majority of our
subjects did not have autopsy-confirmed diagnoses.
Nonetheless, our results have implications for the ability
of oculomotor findings to predict the molecular pathology
associated with these clinical dementia syndromes. Previous
studies have indicated that downward gaze palsy is strongly
predictive of a diagnosis of PSP (with tau protein
deposition) at autopsy (Litvan et al., 1996b). Most clinically
diagnosed PA patients are found to have PSP or CBD
pathology at autopsy (Hodges et al., 2004; Josephs et al.,
2006a) (and the one patient in our series that went to
autopsy had CBD), however the PA group’s eye movements
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associated with CBS or the saccade velocity and gain
changes seen in PSP (Rivaud-Pechoux et al., 2000). Most
SD cases are associated with FTLD-U pathology at autopsy
(Davies et al., 2005), and there are approximately equal
percentages of both FTLD-U and tau pathology found in
clinically diagnosed FTD cases (Forman et al., 2006; Josephs
et al., 2006b). Unlike the SD group, however, we identified
prominent oculomotor abnormalities in our FTD group,
including in two subjects who were found to have FTLD-U
pathology at autopsy.
Taken together, these data suggest that clinical FTLD
syndromes associated with FTLD-U pathology may have no
oculomotor abnormalities (as in SD), abnormalities in
smooth pursuit and anti-saccades (as in FTD) or even
findings similar to PSP (Paviour et al., 2004). Similarly, tau
pathology may be associated with clinical oculomotor
features of decreased saccade velocity and gain (as in
PSP), increased saccade latency (as in CBS) or more subtle
deficits in anti-saccade control and smooth pursuit (as in
PA). While further studies are clearly needed to confirm
these hypotheses, at a minimum our data suggest that
caution should be exercised when attempting to predict the
FTLD-related molecular pathology from isolated clinical
oculomotor findings, except in PSP.
Conclusion
Oculomotor assessment is a component of most standard
neurological examinations. While many of the eye move-
ment variables described in this study require the use of an
eye tracker for accurate measurement, the findings that
were found to be most useful for differentiating groups
(saccade gain and velocity and anti-saccade performance)
can be appreciated at the bedside. Although further studies
will be necessary to determine the utility of bedside
oculomotor testing relative to laboratory measurements,
the results suggest examination of eye movements can
provide important diagnostic information when attempt-
ing to differentiate CBS, PSP, FTLD and Alzheimer’s
disease.
Supplementary material
Supplementary material is available at Brain online.
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